scholarly journals Erectile dysfunction in men with diabetes (literature review) Part 1

2021 ◽  
Vol 17 (5) ◽  
pp. 426-434
Author(s):  
E.V. Luchytskyy ◽  
V.Ye. Luchytskiy
Keyword(s):  
Quality Of Life ◽  
Diabetes Mellitus ◽  
Risk Factor ◽  
Erectile Dysfunction ◽  
Rating Scale ◽  
Sexual Experience ◽  
Clinical Manifestations ◽  
Phosphodiesterase Type 5 Inhibitors ◽  
Patients With Diabetes

The first part of the review article highlights modern views on the prevalence, etiology and features of the pathogenesis of erectile dysfunction (ED) in men with diabetes mellitus. Google Scholar and PubMed databases were used to search for literature sources. The role of comorbid diseases in the development of ED in men with diabetes mellitus has been shown. The generalized data on the main clinical manifestations of erectile dysfunction, methods of its diagnosis and treatment are given. A number of epidemiological studies over the past 20 years have found that erectile dysfunction in men with diabetes may be an early marker of cardiovascular complications. Thus, in the algorithm for ED diagnosis in patients with diabetes it is necessary to conduct a thorough examination of the cardiovascular system. Numerous literature sources indicate an important role in the correction of androgen deficiency in men with type 2 diabetes, in order to enhance the effectiveness of phosphodiesterase type 5 inhibitors. Erectile dysfunction involves a change in any of the components of an erectile response. ED can negatively affect a man’s quality of life because most patients experience symptoms of depression and anxiety related to their sexual capabilities. These symptoms also affect a partner’s sexual experience and the couple’s quality of life. Clinical features of ED have many key features in the anamnesis, including some physical signs during examination depending on a type of diabetes. With age, comorbid conditions play an increasing role in the development of ED. Diabetes mellitus, cardiovascular diseases, obesity can lead to the development of ED before accelerated deterioration of erectile function and disorders at the molecular level of the mechanisms underlying erection. Patients with diabetes and ED have higher scores on the depression rating scale, and poorer overall health and quality of life. Early detection of ED in individuals with diabetes can improve the overall health and quality of life of patients. Patients with diabetes with poor glycemic control and older age are more likely to develop severe ED, which further exacerbates an already compromised health and quality of life. According to the National Health and Nutrition Examination Survey (2001–2002), diabetes mellitus is a modified risk factor independently associated with the development of ED (odds ratio (OR) 2.69), obesity (OR 1.60), smoking (OR 1.74) and hypertension (OR 1.56). Erectile dysfunction is a common complication of diabetes, and diabetes is a risk factor for ED; men with diabetes are three times more likely to have ED.

scholarly journals The use of phosphodiesterase type 5 (pde-5) inhibitors in treatment of erectile dysfunction in patients with diabetes mellitus of different age groups

2014 ◽  
Vol 95 (1) ◽  
pp. 31-35
Author(s):  
T V Mehtiyev
Keyword(s):  
Diabetes Mellitus ◽  
Erectile Dysfunction ◽  
Rating Scale ◽  
Age Groups ◽  
Control Group ◽  
Type I ◽  
Male Hypogonadism ◽  
Phosphodiesterase Type 5 Inhibitors ◽  
Patients With Diabetes ◽  
Phosphodiesterase Type

Aim. To study the effect of phosphodiesterase type 5 inhibitors used to treat the erectile dysfunction in patients of different age groups with concomitant diabetes mellitus. Methods. The study included 293 patients with diabetes mellitus type I and II aged 17-60 years, with duration of diabetes varying from 6 months to 29 years, duration of erectile dysfunction - from 6 months to 12 years. To diagnose the erectile dysfunction, an international index of erectile function, together with routine and special methods were used. Patients were administered phosphodiesterase type 5 inhibitors: sildenafil, taladafil and vardenafil. The control group included men with the erectile dysfunction without diabetes. To identify the male hypogonadism, patients were examined depending on the age group: 18-29 years, 30-39 years, 40-49 years, 50-59 years. Patiens were tested for sex hormones level, male ageing questionnaires were administered. Results. The increased rate of hypogonadism (from 12.5 to 54%) was associated with older age in patients with diabetes mellitus. The androgen status index in patients with diabetes mellitus, according to the Aging Males’ Symptoms rating scale, was 37.1±1.4 points. Phosphodiesterase type 5 inhibitors were more effective in younger age groups (57.1-91.7%) compared to older (36.8-67.3%). When comparing the study drugs, vardenafil showed better effect and relatively few side effects. Conclusion. Androgen deficiency, developing with increasing age is accompanied by a decrease in phosphodiesterase type 5 inhibitors efficiency. The use of small doses of these drugs corresponding the circadian rhythm of testosterone in males with normal testosterone blood level has the same effect as large doses.

scholarly journals Erectile dysfunction as a manifestation of urogenital autonomic neuropathy in patients with type 1 diabetes: epidemiology, classification, pathophysiology, diagnosis and treatment options

2014 ◽  
Vol 17 (2) ◽  
pp. 126-132
Author(s):  
Gagik Radikovich Galstyan ◽  
Yana Grigor'evna Shwarts ◽  
Sergey Anatol'evich Dubsky ◽  
Alexander Evgen'evich Lepetukhin ◽  
Roman Viktorovich Rozhivanov ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Diabetes Mellitus ◽  
Erectile Dysfunction ◽  
Social Life ◽  
Treatment Options ◽  
Significant Decline ◽  
Sexual Disorder ◽  
Patients With Diabetes

Sexual dysfunction characterized by a significant decline in the quality of life of patients and leading to infertility and problems in social life is diagnosed in more than 40% of patients with diabetes mellitus (DM). Erectile dysfunction is the most common sexual disorder in DM patients. The article describes epidemiology, classification, pathophysiology, diagnostic and treatment of erectile dysfunction in T1DM patients.

Quality of Life and Suicide Risk in Patients With Diabetes Mellitus

2009 ◽  
Vol 50 (1) ◽  
pp. 16-23 ◽  
Author(s):  
Maurizio Pompili ◽  
David Lester ◽  
Marco Innamorati ◽  
Eleonora De Pisa ◽  
Mario Amore ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Diabetes Mellitus ◽  
Suicide Risk ◽  
Patients With Diabetes

scholarly journals Quality of life of patients with diabetes mellitus: Social domain of health

SANAMED ◽  
2014 ◽  
Vol 9 (2) ◽  
pp. 151-159
Author(s):  
Dragana Grujic-Vujmilovic ◽  
Zivana Gavric
Keyword(s):  
Quality Of Life ◽  
Diabetes Mellitus ◽  
Social Domain ◽  
Patients With Diabetes

scholarly journals INTERRELATION BETWEEN THE CHANGES IN QUALITY OF LIFE AND ARTERIAL STIFFNESS IN PATIENTS WITH DIABETES MELLITUS TYPE 2 AND CONCOMITANT OBESITY

2018 ◽  
Vol 18 (4) ◽  
pp. 71-75
Author(s):  
I.M. Fushtey ◽  
Ye.A. Solovyuk ◽  
A.O. Solovyuk
Keyword(s):  
Quality Of Life ◽  
Physical Activity ◽  
Diabetes Mellitus ◽  
Emotional State ◽  
Eating Behaviour ◽  
Overweight And Obesity ◽  
Healthy Individuals ◽  
Patients With Diabetes

The purpose of this work was to study the general characteristics of quality of life (QoL), the effect of overweight on QoL, the nature of eating behaviour in patients with diabetes mellitus (DM) type 2 and   concomitant overweight (OW) and obesity, as well as to establish the correlation with indicators of functional state of the arterial vessels. 64 people (34 women and 30 men) with DM and concomitant  overweight and obesity (average age 56.3 ± 10.23 years) formed the 1 group, 34 people (19 women and 15 men), whose average age was 55.6 ± 11.92 years constituted the 2 group, and  28 healthy individuals formed the control group. SF-36v2 questionnaires were used to evaluate QoL. The effect of overweight on QoL was analyzed according to the IWQOL-Lite questionnaire data, the patterns of eating behaviour were determined by the COEQ4 for 7 days using FPRS questionnaire. The functional state of the arterial vessels was assessed by estimating the pulse wave velocity using the automated rheographic complex ReoCom (KhAI Medika (Ukraine)). The patients with DM and concomitant overweight and obesity were found to experience some changes in QoL according to the SF-36v2 questionnaire. The changes were primarily characterized by a decrease in physical activity, as well as in social and emotional status. These changes differed not only from the QoL assessment by healthy individuals, but also from those of patients with DM and normal body weight. The nature of eating behaviour in overweight or obese patients with DM was characterized by an increased hunger in parallel with a worsened emotional state and an increased desire to eat certain types of foods that can contribute to weight gain. Structural changes in arterial vessels that typically are indicative of arterial stiffness correlate with indicators of emotional state and physical activity in patients with DM and comorbid overweight and obesity.

scholarly journals Diabetes-dependent quality of life (ADDQOL) and affecting factors in patients with diabetes mellitus type 2 in Greece

2015 ◽  
Vol 8 (1) ◽  
Author(s):  
Athanasia K. Papazafiropoulou ◽  
Florentia Bakomitrou ◽  
Aikaterini Trikallinou ◽  
Asimina Ganotopoulou ◽  
Chris Verras ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Diabetes Mellitus ◽  
Diabetes Mellitus Type 2 ◽  
Diabetes Mellitus Type ◽  
Affecting Factors ◽  
Patients With Diabetes

Drugs

ESC CardioMed ◽  
2018 ◽  
pp. 1030-1035
Author(s):  
Mike Kirby ◽  
Jonny Coxon
Keyword(s):  
Quality Of Life ◽  
Cardiovascular Disease ◽  
Erectile Dysfunction ◽  
Negative Effects ◽  
Phosphodiesterase Type 5 Inhibitors ◽  
Cardiac Condition ◽  
Male Patients ◽  
Phosphodiesterase Type ◽  
The Impact

It should not be presumed that male patients with cardiovascular disease are less sexually active than others, but they are more likely to have erectile dysfunction. It is therefore crucial to consider the impact on sexual function of medications commonly used to treat cardiovascular disease, because negative effects on erectile dysfunction can lead to problems with compliance and quality of life. Cardiovascular implications of phosphodiesterase type 5 inhibitors used to treat erectile dysfunction should be borne in mind. Effective treatment of the cardiac condition should always take priority.

Sign in / Sign up

Export Citation Format

Share Document